Journal
CLINICAL CANCER RESEARCH
Volume 17, Issue 16, Pages 5226-5232Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-0171
Keywords
-
Categories
Funding
- European Research Council [243128/TIE2+Monocytes, 249845/TARGETINGGENETHERAPY]
- Associazione Italiana per la Ricerca sul Cancro [IG-2007, IG-2010]
- Italian Ministry of Health
- AstraZeneca
- Fondazione Telethon Funding Source: Custom
Ask authors/readers for more resources
Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed. Clin Cancer Res; 17(16); 5226-32. (C)2011 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available